
SEC Form 424B5 filed by Senti Biosciences Inc.

• | exemption from the requirement to have our registered independent public accounting firm attest to management’s assessment of our internal control over financial reporting; |
• | exemption from compliance with the requirement of the Public Company Accounting Oversight Board, or PCAOB, regarding the communication of critical audit matters in the auditor’s report on the financial statements; |
• | reduced disclosure about our executive compensation arrangements; and exemption from the requirement to hold non-binding advisory votes on executive compensation or golden parachute arrangements. |
• | 1,333,030 shares of common stock issuable upon the exercise of stock options outstanding at a weighted-average exercise price of $36.36 per share; |
• | 31,735,500 shares of common stock issuable upon the exercise of warrants to purchase shares of common stock outstanding at a weighted-average exercise price of $2.30 per share; |
• | 56,423 shares of common stock issuable upon the vesting and settlement of outstanding restricted stock units, or RSUs, under our equity incentive plans at a weighted-average grant date fair value of $4.56 per share; |
• | 4,446,809 shares of common stock available for issuance under our Amended and Restated 2022 Equity Incentive Plan, or 2022 Plan, plus any future increases in the number of shares of common stock reserved for issuance under our 2022 Plan pursuant to the evergreen provision of our 2022 Plan; |
• | 79,387 shares of common stock available for issuance under our 2022 Employee Stock Purchase Plan, or ESPP, plus any future increases in the number of shares of common stock reserved for issuance under our ESPP pursuant to the evergreen provision of our ESPP; and |
• | 624,098 shares of common stock available for issuance under our Amended and Restated 2022 Inducement Plan, or Inducement Plan. |
• | the initiation, cost, timing, progress and results of our clinical trials, preclinical studies or research and development activities with respect to our current and potential future product candidates; |
• | the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates; |
• | our ability to develop and advance our gene circuit platform technologies and to identify product candidates using our gene circuit platform technologies; |
• | our ability to advance our current and potential future product candidates into, and successfully initiate, conduct, enroll and complete clinical trials; |
• | our ability to develop and commercialize product candidates that we identify; |
• | our ability to obtain and maintain regulatory approval of our current and potential future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; |
• | our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture; |
• | our ability to source clinical and, if approved, commercial materials and supplies used to manufacture our product candidates; |
• | the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers; |
• | our ability to realize the benefits expected from the Framework Agreement and subsequent amendment, dated August 7, 2023 and December 10, 2024, respectively, by and among us, GeneFab, LLC and Valere Bio, Inc., and the transactions contemplated thereunder; |
• | our ability to meet the milestone requirements and receive the grants from California Institute of Regenerative Medicines as well as the timing of such grants; |
• | our projected financial information, anticipated growth rate, and market opportunities; |
• | the accuracy of our estimates and projections of financial information, including expenses, capital requirements, cash utilization, need for additional financing and market opportunities; |
• | our ability to maintain the listing of our common stock on Nasdaq, and the potential liquidity and trading of such securities; |
• | our ability to continue our strategic collaboration with Celest Therapeutics in China for SN301A, Celest Therapeutics’ product candidate that incorporates the SENTI-301A gene circuit, or SN301A, and the timing as well as the success of ongoing clinical trials with Celest Therapeutics in China; |
• | our ability to file and obtain clearance for any additional investigational new drug application, or IND, for any additional product candidates we may identify, and to successfully complete our ongoing Phase 1 clinical trial for SENTI-202 and additional clinical trials for any potential future product candidates; |
• | our ability to grow and effectively manage the growth of our operations; |
• | our ability to raise financing to fund our operations, if and when needed; |
• | our ability to obtain and maintain intellectual property protection for our technologies and any of our product candidates; |
• | our ability to successfully commercialize our current and any potential future product candidates; |
• | the rate and degree of market acceptance of our current and any potential future product candidates; |
• | regulatory developments in the United States and international jurisdictions; |
• | the potential benefits of strategic collaboration agreements and our ability, and the ability of our collaborators, to successfully develop technologies and product candidates under the respective collaborations; |
• | the potential liability from lawsuits and penalties related to our technologies, product candidates and current and future relationships with third parties, including relationships under strategic and financing transactions; |
• | our success in retaining or recruiting, or adapting to changes in, our officers, key employees, or directors; |
• | our ability to attract and retain key scientific and management personnel; |
• | our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements; |
• | our ability to compete effectively with existing competitors and new market entrants; |
• | our future financial performance and capital requirements; |
• | our ability to implement and maintain effective internal controls; |
• | the impact of supply chain disruptions; |
• | the impact of any global health crises on our business, including our ongoing and potential future clinical trials and preclinical studies; |
• | any impacts on our business from unfavorable global economic conditions, including significant political, trade or regulatory developments, inflationary pressures, market volatility, acts of war and civil and political unrest; |
• | our ability to implement remediation plans to address the material weaknesses that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024; |
• | our expectations regarding the period during which we qualify as a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and “emerging growth company” under the Jumpstart Our Business Startups Act of 2012; and |
• | other factors detailed under the section entitled “Risk Factors” in this prospectus, any prospectus supplement, and any documents incorporated by reference herein or therein. |
Assumed offering price per share | $3.62 | |||||
Net tangible book value per share as of December 31, 2024 | $1.11 | |||||
Increase in net tangible book value per share attributable to new investors in offering | $0.35 | |||||
As adjusted net tangible book value per share as of December 31, 2024, after giving effect to the offering | $1.46 | |||||
Dilution per share to investors participating in this offering | $2.16 | |||||
• | 1,333,030 shares of common stock issuable upon the exercise of stock options outstanding at a weighted-average exercise price of $36.36 per share; |
• | 31,735,500 shares of common stock issuable upon the exercise of warrants to purchase shares of common stock outstanding at a weighted-average exercise price of $2.30 per share; |
• | 56,423 shares of common stock issuable upon the vesting and settlement of outstanding RSUs under our equity incentive plans at a weighted-average grant date fair value of $4.56 per share; |
• | 4,446,809 shares of common stock available for issuance under our 2022 Plan, plus any future increases in the number of shares of common stock reserved for issuance under our 2022 Plan pursuant to the evergreen provision of our 2022 Plan; |
• | 79,387 shares of common stock available for issuance under our ESPP, plus any future increases in the number of shares of common stock reserved for issuance under our ESPP pursuant to the evergreen provision of our ESPP; and |
• | 624,098 shares of common stock available for issuance under our Inducement Plan. |
• | Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 20, 2025; |
• | Current Reports on Form 8-K filed with the SEC on January 6, 2025, February 6, 2025, February 25, 2025, March 7, 2025, March 10, 2025 (excluding information furnished pursuant to Items 2.02 or 7.01, or corresponding information furnished under Item 9.01 or included as an exhibit); and |
• | The description of our securities attached as Exhibit 4.3 our Annual Report on Form 10-K filed with the SEC on March 20, 2025, including any amendments or reports filed for the purpose of updating such description. |

• | the initiation, cost, timing, progress and results of our clinical trials, preclinical studies or research and development activities with respect to our current and potential future product candidates; |
• | the therapeutic potential of our product candidates, and the disease indications for which we intend to develop our product candidates; |
• | our ability to develop and advance our gene circuit platform technologies and to identify product candidates using our gene circuit platform technologies; |
• | our ability to advance our current and potential future product candidates into, and successfully initiate, conduct, enroll and complete clinical trials; |
• | our ability to develop and commercialize product candidates that we identify; |
• | our ability to obtain and maintain regulatory approval of our current and potential future product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; |
• | our ability to manufacture our product candidates for clinical development and, if approved, for commercialization, and the timing and costs of such manufacture; |
• | our ability to source clinical and, if approved, commercial materials and supplies used to manufacture our product candidates; |
• | the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers; |
• | our ability to realize the benefits expected from the Framework Agreement and subsequent amendment, dated August 7, 2023 and December 10, 2024, respectively, by and among us, GeneFab, LLC and Valere Bio, Inc., and the transactions contemplated thereunder; |
• | our ability to meet the milestone requirements and receive the grants from California Institute of Regenerative Medicines as well as the timing of such grants; |
• | our projected financial information, anticipated growth rate, and market opportunities; |
• | the accuracy of our estimates and projections of financial information, including expenses, capital requirements, cash utilization , need for additional financing and market opportunities; |
• | our ability to maintain the listing of our common stock on Nasdaq, and the potential liquidity and trading of such securities; |
• | our ability to continue our strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd, or Celest Therapeutics, in China for SN301A, Celest Therapeutics’ product candidate that incorporates the SENTI-301A gene circuit, or SN301A, and the timing as well as the success of ongoing clinical trials with Celest Therapeutics in China; |
• | our ability to file and obtain clearance for any additional investigational new drug application, or IND, for any additional product candidates we may identify, and to successfully complete our ongoing Phase 1 clinical trial for SENTI-202 and additional clinical trials for any potential future product candidates; |
• | our ability to grow and effectively manage the growth of our operations; |
• | our ability to raise financing to fund our operations, if and when needed; |
• | our ability to obtain and maintain intellectual property protection for our technologies and any of our product candidates; |
• | our ability to successfully commercialize our current and any potential future product candidates; |
• | the rate and degree of market acceptance of our current and any potential future product candidates; |
• | regulatory developments in the United States and international jurisdictions; |
• | the potential benefits of strategic collaboration agreements and our ability, and the ability of our collaborators, to successfully develop technologies and product candidates under the respective collaborations; |
• | the potential liability from lawsuits and penalties related to our technologies, product candidates and current and future relationships with third parties, including relationships under strategic and financing transactions; |
• | our success in retaining or recruiting, or adapting to changes in, our officers, key employees, or directors; |
• | our ability to attract and retain key scientific and management personnel; |
• | our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately under those arrangements; |
• | our ability to compete effectively with existing competitors and new market entrants; |
• | our future financial performance and capital requirements; |
• | our ability to implement and maintain effective internal controls; |
• | the impact of supply chain disruptions; |
• | the impact of any global health crises on our business, including our ongoing and potential future clinical trials and preclinical studies; |
• | any impacts on our business from unfavorable global economic conditions, including significant political, trade or regulatory developments, inflationary pressures, market volatility, acts of war and civil and political unrest; |
• | our ability to implement remediation plans to address the material weaknesses that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024; |
• | our expectations regarding the period during which we qualify as a “smaller reporting company” as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and “emerging growth company” under the Jumpstart Our Business Startups Act of 2012; and |
• | other factors detailed under the section entitled “Risk Factors” in this prospectus, any prospectus supplement, and any documents incorporated by reference herein or therein. |
• | exemption from the requirement to have our registered independent public accounting firm attest to management’s assessment of our internal control over financial reporting; |
• | exemption from compliance with the requirement of the Public Company Accounting Oversight Board, or PCAOB, regarding the communication of critical audit matters in the auditor’s report on the financial statements; |
• | reduced disclosure about our executive compensation arrangements; and exemption from the requirement to hold non-binding advisory votes on executive compensation or golden parachute arrangements. |
• | designation or classification; |
• | aggregate principal amount or aggregate offering price; |
• | voting or other rights; |
• | rates and times of payment of interest, dividends or other payments, if any; |
• | liquidation preference; |
• | original issue discount, if any; |
• | maturity date, if applicable; |
• | ranking; |
• | restrictive covenants, if any; |
• | redemption, conversion, exercise, exchange, settlement or sinking fund terms, including prices or rates, if any, and, if applicable, any provisions for changes to or adjustments in such prices or rates and in the securities or other property receivable upon conversion, exercise, exchange or settlement; |
• | any securities exchange or market listing arrangements; and |
• | important U.S. federal income tax considerations, if any. |
• | permit our Board to issue up to 10,000,000 shares of preferred stock, of which 21,200 shares have been designated Series A Preferred Stock, as described above under the section titled “—Preferred Stock,” with any rights, preferences and privileges as they may designate, including the right to approve an acquisition or other change of control; |
• | provide that our number of directors may be changed only by resolution of our Board; |
• | provide that, subject to the rights of any series of preferred stock to elect directors, directors may be removed only with cause by the holders of at least 75% of all of our then-outstanding shares of the capital stock entitled to vote generally at an election of directors; |
• | provide that all vacancies, subject to the rights of any series of preferred stock, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; |
• | provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice; |
• | provide that special meetings of our stockholders may be called by our Board pursuant to a resolution adopted by a majority of the board; |
• | provide that our Board o will be divided into three classes of directors, with the directors serving three-year terms, therefore making it more difficult for stockholders to change the composition of our Board; and |
• | not provide for cumulative voting rights, therefore allowing the holders of a majority of our common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose. |
• | a stockholder who owns 15% or more of our outstanding voting stock, otherwise known as an “interested stockholder”; |
• | an affiliate of an interested stockholder; or |
• | an associate of an interested stockholder, for three years following the date that the stockholder became an interested stockholder. |
• | A “business combination” includes a merger or sale of more than 10% of a corporation’s assets. However, the above provisions of Section 203 would not apply if: |
• | the relevant board of directors approves the transaction that made the stockholder an “interested stockholder,” prior to the date of the transaction; |
• | after the completion of the transaction that resulted in the stockholder becoming an interested stockholder, that stockholder owned at least 85% of the corporation’s voting stock outstanding at the time the transaction commenced, other than statutorily excluded shares of common stock; or |
• | on or subsequent to the date of the transaction, the initial business combination is approved by the board of directors and authorized at a meeting of the corporation’s stockholders, and not by written consent, by an affirmative vote of at least two-thirds of the outstanding voting stock not owned by the interested stockholder. |
• | the title; |
• | the principal amount being offered, and if a series, the total amount authorized and the total amount outstanding; |
• | any limit on the amount that may be issued; |
• | whether or not we will issue the series of debt securities in global form, and, if so, the terms and who the depository will be; |
• | the maturity date; |
• | whether and under what circumstances, if any, we will pay additional amounts on any debt securities held by a person who is not a United States person for tax purposes, and whether we can redeem the debt securities if we have to pay such additional amounts; |
• | the annual interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; |
• | whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; |
• | the terms of the subordination of any series of subordinated debt; |
• | the place where payments will be payable; |
• | restrictions on transfer, sale or other assignment, if any; |
• | our right, if any, to defer payment of interest and the maximum length of any such deferral period; |
• | the date, if any, after which, the conditions upon which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; |
• | the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder’s option, to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; |
• | whether the indenture will restrict our ability or the ability of our subsidiaries to: |
○ | incur additional indebtedness; |
○ | issue additional securities; |
○ | create liens; |
○ | pay dividends or make distributions in respect of our capital stock or the capital stock of our subsidiaries; |
○ | redeem capital stock; |
○ | place restrictions on our subsidiaries’ ability to pay dividends, make distributions or transfer assets; |
○ | make investments or other restricted payments; |
○ | sell or otherwise dispose of assets; |
○ | enter into sale-leaseback transactions; |
○ | engage in transactions with stockholders or affiliates; |
○ | issue or sell stock of our subsidiaries; or |
○ | effect a consolidation or merger; |
• | whether the indenture will require us to maintain any interest coverage, fixed charge, cash flow-based, asset-based or other financial ratios; |
• | a discussion of certain material or special United States federal income tax considerations applicable to the debt securities; |
• | information describing any book-entry features; |
• | provisions for a sinking fund purchase or other analogous fund, if any; |
• | the applicability of the provisions in the indenture on discharge; |
• | whether the debt securities are to be offered at a price such that they will be deemed to be offered at an “original issue discount” as defined in paragraph (a) of Section 1273 of the Internal Revenue Code of 1986, as amended; |
• | the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; and |
• | the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; and any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, including any additional events of default or covenants provided with respect to the debt securities, and any terms that may be required by us or advisable under applicable laws or regulations or advisable in connection with the marketing of the debt securities. |
• | if we fail to pay interest when due and payable and our failure continues for 90 days and the time for payment has not been extended; |
• | if we fail to pay the principal, premium or sinking fund payment, if any, when due and payable at maturity, upon redemption or repurchase or otherwise, and the time for payment has not been extended; |
• | if we fail to observe or perform any other covenant contained in the debt securities or the indentures, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive notice from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and |
• | if specified events of bankruptcy, insolvency or reorganization occur. |
• | the direction so given by the holder is not in conflict with any law or the applicable indenture; and |
• | subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. |
• | the holder has given written notice to the trustee of a continuing event of default with respect to that series; |
• | the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the trustee or security satisfactory to it against any loss, liability or expense or to be incurred in compliance with instituting the proceeding as trustee; and |
• | the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. |
• | to fix any ambiguity, defect or inconsistency in the indenture; |
• | to comply with the provisions described above under “Description of Our Debt Securities—Consolidation, Merger or Sale;” |
• | to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act; |
• | to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; |
• | to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided under “Description of Our Debt Securities—General,” to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; |
• | to evidence and provide for the acceptance of appointment hereunder by a successor trustee; |
• | to provide for uncertificated debt securities and to make all appropriate changes for such purpose; |
• | to add to our covenants such new covenants, restrictions, conditions or provisions for the benefit of the holders, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred to us in the indenture; or |
• | to change anything that does not materially adversely affect the interests of any holder of debt securities of any series. |
• | extending the stated maturity of the series of debt securities; |
• | reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption or repurchase of any debt securities; or |
• | reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. |
• | register the transfer or exchange of debt securities of the series; |
• | replace stolen, lost or mutilated debt securities of the series; |
• | maintain paying agencies; |
• | hold monies for payment in trust; |
• | recover excess money held by the trustee; |
• | compensate and indemnify the trustee; and |
• | appoint any successor trustee. |
• | issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or |
• | register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. |
• | the offering price and aggregate number of warrants offered; |
• | the currency for which the warrants may be purchased; |
• | if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; |
• | if applicable, the date on and after which the warrants and the related securities will be separately transferable; |
• | in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; |
• | in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; |
• | the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and the warrants; |
• | the terms of any rights to redeem or call the warrants; |
• | any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; |
• | the periods during which, and places at which, the warrants are exercisable; |
• | the manner of exercise; |
• | the dates on which the right to exercise the warrants will commence and expire; |
• | the manner in which the warrant agreement and warrants may be modified; |
• | federal income tax consequences of holding or exercising the warrants; |
• | the terms of the securities issuable upon exercise of the warrants; and |
• | any other specific terms, preferences, rights or limitations of or restrictions on the warrants. |
• | the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; |
• | any provisions of the governing unit agreement; |
• | the price or prices at which such units will be issued; |
• | the applicable United States federal income tax considerations relating to the units; |
• | any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; and |
• | any other terms of the units and of the securities comprising the units. |
• | to cure any ambiguity; any provisions of the governing unit agreement that differ from those described below; |
• | to correct or supplement any defective or inconsistent provision; or |
• | to make any other change that we believe is necessary or desirable and will not adversely affect the interests of the affected holders in any material respect. |
• | impair any right of the holder to exercise or enforce any right under a security included in the unit if the terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or |
• | reduce the percentage of outstanding units or any series or class the consent of whose holders is required to amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. |
• | If the change affects only the units of a particular series issued under that agreement, the change must be approved by the holders of a majority of the outstanding units of that series; or |
• | If the change affects the units of more than one series issued under that agreement, it must be approved by the holders of a majority of all outstanding units of all series affected by the change, with the units of all the affected series voting together as one class for this purpose. |
• | Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost, stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions or perform them ourselves. |
• | Holders will not be required to pay a service charge to transfer or exchange their units, but they may be required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder’s proof of legal ownership. The transfer agent may also require an indemnity before replacing any units. |
• | If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right as to less than all those units or other securities, we may block the exchange or transfer of those units during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. |
• | through underwriters; |
• | through dealers; |
• | through agents; |
• | directly to one or more purchasers, including to a limited number of institutional purchasers, to a single purchaser or to our affiliates and stockholders; |
• | in “at the market offerings,” within the meaning of Rule 415(a)(4) of the Securities Act, to or through a market maker or into an existing trading market, on an exchange or otherwise; or |
• | through a combination of any of these methods or any other method permitted by law. |
• | at a fixed price, or prices, which may be changed from time to time; |
• | at market prices prevailing at the time of sale; |
• | at prices related to such prevailing market prices; or |
• | at negotiated prices. |
• | the terms of the offerings; |
• | the names of any underwriters, dealers or agents; |
• | the name or names of any managing underwriter or underwriters; |
• | the public offering or purchase price of the securities; |
• | the net proceeds from the sale of securities; |
• | any delayed delivery arrangements; |
• | any discounts and commissions to be allowed or paid to the underwriters, dealers or agents; |
• | all other items constituting underwriting compensation; |
• | any discounts and commissions to be allowed or reallowed or paid to dealers; |
• | any commissions paid to agents; and |
• | any exchanges on which the securities will be listed. |
• | the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of the jurisdiction to which that institution is subject; and |
• | if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts. |
• | Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 20, 2025; |
• | Current Reports on Form 8-K filed with the SEC on January 6, 2025, February 6, 2025, February 25, 2025, March 7, 2025, March 10, 2025 (excluding information furnished pursuant to Items 2.02 or 7.01, or corresponding information furnished under Item 9.01 or included as an exhibit); and |
• | The description of our securities attached as Exhibit 4.3 to our Annual Report on Form 10-K filed with the SEC on March 20, 2025, including any amendments or reports filed for the purpose of updating such description. |